[Topoisomerase II inhibitors (anthracyclines)]. 2015

Atsushi Sato, and Takenori Takahata, and Kensuke Saito

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012871 Skin Diseases Diseases involving the DERMIS or EPIDERMIS. Dermatoses,Skin and Subcutaneous Tissue Disorders,Dermatosis,Skin Disease
D059005 Topoisomerase II Inhibitors Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. DNA Gyrase Inhibitor,DNA Topoisomerase II Inhibitor,Topoisomerase 2 Inhibitors,Topoisomerase II Inhibitor,DNA Gyrase Inhibitors,DNA Topoisomerase II Inhibitors,DNA Type 2 Topoisomerase Inhibitors,Gyrase Inhibitor, DNA,Gyrase Inhibitors, DNA,II Inhibitor, Topoisomerase,Inhibitor, DNA Gyrase,Inhibitor, Topoisomerase II,Inhibitors, DNA Gyrase,Inhibitors, Topoisomerase 2,Inhibitors, Topoisomerase II
D018943 Anthracyclines Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine. Anthracycline

Related Publications

Atsushi Sato, and Takenori Takahata, and Kensuke Saito
January 2005, Cancer chemotherapy and biological response modifiers,
Atsushi Sato, and Takenori Takahata, and Kensuke Saito
January 2003, Cancer chemotherapy and biological response modifiers,
Atsushi Sato, and Takenori Takahata, and Kensuke Saito
January 2002, Cancer chemotherapy and biological response modifiers,
Atsushi Sato, and Takenori Takahata, and Kensuke Saito
January 2001, Cancer chemotherapy and biological response modifiers,
Atsushi Sato, and Takenori Takahata, and Kensuke Saito
January 2000, IARC monographs on the evaluation of carcinogenic risks to humans,
Atsushi Sato, and Takenori Takahata, and Kensuke Saito
November 2018, International journal of molecular sciences,
Atsushi Sato, and Takenori Takahata, and Kensuke Saito
November 1990, Anti-cancer drug design,
Atsushi Sato, and Takenori Takahata, and Kensuke Saito
May 2009, Journal of environmental biology,
Atsushi Sato, and Takenori Takahata, and Kensuke Saito
January 2006, Acta poloniae pharmaceutica,
Copied contents to your clipboard!